Humulin I (Isophane) (Insulin Human)

Humulin I (Isophane) is indicated for the management of hyperglycemia in patients with diabetes mellitus. It is used as part of a comprehensive diabetes treatment plan that may include diet, exercise, and other glucose‑lowering agents.

• Type 1 diabetes mellitus requiring basal insulin coverage.
• Type 2 diabetes mellitus when basal insulin is indicated.
• Adjunct therapy in patients transitioning from short‑acting insulin regimens.
• Use in combination with rapid‑acting insulin analogues for basal‑bolus therapy.
• Situations where a steady, intermediate‑acting insulin profile is preferred.

• Humulin I (Isophane) contains insulin human that binds to insulin receptors on muscle, adipose, and hepatic cells. Receptor activation triggers the tyrosine kinase pathway, promoting translocation of GLUT‑4 transporters to the cell surface and enhancing glucose uptake. In the liver, the insulin signal suppresses gluconeogenesis and glycogenolysis, reducing endogenous glucose production. The protamine component prolongs absorption, creating an intermediate‑duration insulin effect.

Adverse reactions to Humulin I (Isophane) can vary in frequency and severity. Patients should be aware of both common and potentially serious events.

Common

• Hypoglycemia, especially if meals are delayed or doses are mismatched.
• Injection site reactions such as redness, swelling, or itching.
• Lipodystrophy, including lipoatrophy or lipohypertrophy at the injection site.
• Weight gain associated with improved glycemic control.
• Localized bruising or bleeding at the injection site.
• Localized bruising or bleeding at the injection site.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic reactions ranging from urticaria to anaphylaxis.
• Edema or fluid retention, particularly in patients with cardiac or renal disease.
• Rare cases of insulin antibody formation causing resistance.
• Hypersensitivity reactions that may progress to serum sickness.

When prescribing or using Humulin I (Isophane), clinicians and patients should consider several precautionary measures to minimize risks and ensure optimal therapy.

• Assess renal and hepatic function before initiating therapy and monitor periodically.
• Adjust doses in patients with fluctuating dietary intake or physical activity.
• Use caution in pregnant or breastfeeding women; benefits must outweigh potential risks.
• Avoid use in patients with known hypersensitivity to insulin or protamine.
• Educate patients on proper injection technique to prevent lipodystrophy.
• Monitor for signs of hypoglycemia, especially in the elderly or those on concomitant glucose‑lowering drugs.
• Review concomitant medications that may mask hypoglycemia symptoms.

Humulin I (Isophane) may interact with other agents that affect blood glucose or insulin metabolism. Recognizing these interactions helps to avoid adverse events.

Avoid

• Concurrent use of other insulin products without dose adjustment.
• Beta‑blockers that can mask hypoglycemia symptoms.
• High‑dose corticosteroids that increase insulin resistance.
• MAO inhibitors, which may alter insulin metabolism.

Use with caution

• Oral antidiabetic agents such as sulfonylureas or meglitinides, which may potentiate hypoglycemia.
• ACE inhibitors or ARBs, which can enhance insulin sensitivity.
• Thyroid hormones, as hyperthyroidism may increase insulin requirements.
• Alcohol, especially in excess, which can cause unpredictable glucose fluctuations.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may affect renal function and insulin clearance.